4th Quarter - Report

WALGREEN COMPANY for WALGREEN COMPANY

Firm
Client
Income
—
Expenses
$790,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

H.R. 3179 - the "Market Place Equity Act of 2011," all provisions regarding authorizing states to require all sellers making remote sales to collect and remit sales and use taxes with respect to such sales into the state, without regard to the location of the seller. S. 1832 - the "Marketplace Fairness Act," all provisions regarding authorizing member states under the Streamlined Sales and Use Tax Agreement to require all sellers (minus small seller exception) to collect and remit sales and use taxes with respect to remote sales and allowing a state that is not a member state under the Agreement to require sellers to collect and remit sales and use taxes without respect to remote sales. Issues related to corporate tax reform. No specific legislation.

LobbyistCovered position, as disclosed
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —
HEATHER HERNDON SMITH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3179 (112th), S. 1832 (112th)

Medicare/Medicaid MMM

S. 274 - the "Medication Therapy Management Empowerment Act of 2011," all provisions regarding amending the Medicare Modernization Act to expand the eligibility of all targeted beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D. H.R. 891 - the "Medication Therapy Management (MTM) Benefits Act of 2011," all provisions related to the requirement of MTM services to include person-to-person targeted medication reviews by a licensed pharmacist offered at least every quarter and expand eligibility of all target beneficiaries for access to MTM. Issues relating to Medicares Competitive Bidding program that includes mail order/retail-provided diabetic testing supplies with regards to reimbursements provided to retail pharmacies. No specific legislation.

LobbyistCovered position, as disclosed
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —
HEATHER HERNDON SMITH —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 274 (112th), H.R. 891 (112th)

Pharmacy PHA

H.R. 1971/S. 1058 - the "Pharmacy Competition and Consumer Choice Act of 2011," all provisions related to requirement of Pharmacy Benefit Managers annual reporting to Part D plan sponsors of number and total cost of prescriptions under a contract, payments to pharmacies, payments from pharmaceuticals manufacturers and generic and brand name drugs dispensed. H.R. 4215 - the "Medicare Pharmacy Transparency and Fair Auditing Act," amends Medicare Part D to require each contract entered into with a prescription drug plan (PDP) sponsor for the offering of a prescription drug plan to prohibit PDP sponsor from contracting with any pharmacy benefits manager (PBM) to manage the prescription drug coverage under such plan or control the costs of such coverage, unless the manager satisfies specific PBM audit and disclosure requirements. H.R. 6638, the Supporting Access to Formulated and Effective (SAFE) Compounded Drugs Act, all provisions requiring compounding pharmacies to register their facility with the FDA, requiring compounded drugs to be labeled appropriately, establishing an FDA database on compounding pharmacies and having the FDA set minimum production standards. Issues relating to regulations that would establish an effective drug identification and tracking system through which drug manufacturers, repackagers, wholesale distributors and dispensers may authenticate the wholesale distribution history of any prescription drug that is subject to a requirement for a standardized numerical identifier. No specific legislation.

LobbyistCovered position, as disclosed
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —
HEATHER HERNDON SMITH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4215 (112th), H.R. 6638 (112th), S. 1058 (112th), H.R. 1971 (112th)

Health Issues HCR

H.R. 436 - the "Health Care Cost Reduction Act," all provisions regarding repealing provisions of the Patient Protection and Affordable Care Act that limit payments for medications from health savings accounts and health flexible spending arrangements and reimbursement arrangements to only prescription drugs or insulin.

LobbyistCovered position, as disclosed
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —
HEATHER HERNDON SMITH —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 436 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.